CA3042080A1 - Ror-gamma modulators - Google Patents

Ror-gamma modulators Download PDF

Info

Publication number
CA3042080A1
CA3042080A1 CA3042080A CA3042080A CA3042080A1 CA 3042080 A1 CA3042080 A1 CA 3042080A1 CA 3042080 A CA3042080 A CA 3042080A CA 3042080 A CA3042080 A CA 3042080A CA 3042080 A1 CA3042080 A1 CA 3042080A1
Authority
CA
Canada
Prior art keywords
compound
formula
c6alkyl
hydroxypropan
protocol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3042080A
Other languages
English (en)
French (fr)
Inventor
John Nuss
Jason Harris
Raju Mohan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Escalier Biosciences BV
Original Assignee
Escalier Biosciences BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Escalier Biosciences BV filed Critical Escalier Biosciences BV
Publication of CA3042080A1 publication Critical patent/CA3042080A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Details Of Television Scanning (AREA)
  • Processing Of Color Television Signals (AREA)
  • Picture Signal Circuits (AREA)
CA3042080A 2016-10-27 2017-10-27 Ror-gamma modulators Pending CA3042080A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413907P 2016-10-27 2016-10-27
US62/413,907 2016-10-27
PCT/US2017/058755 WO2018081558A1 (en) 2016-10-27 2017-10-27 Ror-gamma modulators

Publications (1)

Publication Number Publication Date
CA3042080A1 true CA3042080A1 (en) 2018-05-03

Family

ID=62024021

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3042080A Pending CA3042080A1 (en) 2016-10-27 2017-10-27 Ror-gamma modulators

Country Status (14)

Country Link
US (5) US10905687B2 (enExample)
EP (1) EP3532062B1 (enExample)
JP (1) JP7027437B2 (enExample)
KR (1) KR102598775B1 (enExample)
CN (1) CN110139652B (enExample)
AU (1) AU2017348345B2 (enExample)
BR (1) BR112019008548A2 (enExample)
CA (1) CA3042080A1 (enExample)
ES (1) ES2928904T3 (enExample)
IL (1) IL266261B (enExample)
MX (1) MX392163B (enExample)
PH (1) PH12019500949A1 (enExample)
RU (1) RU2753490C2 (enExample)
WO (1) WO2018081558A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2928904T3 (es) 2016-10-27 2022-11-23 Escalier Biosciences Bv Moduladores de ROR-gamma
JP2021517563A (ja) 2018-03-12 2021-07-26 エスカリア バイオサイエンシーズ，ビーブイ 二環式ＲＯＲγモジュレーター
EA202092051A1 (ru) 2018-03-12 2021-03-04 Эскальер Байосайенсес Б.В. Спироциклические модуляторы ror-гамма
AU2020378005A1 (en) * 2019-11-05 2022-05-26 Dermira, Inc. ROR gamma T inhibitors and topical uses thereof
IL298928A (en) * 2020-06-30 2023-02-01 Dermira Inc RORγt INHIBITORS AND TOPICAL USES THEREOF
CN111892599B (zh) * 2020-08-14 2023-01-13 黄芳 一种2,5-二氮杂双环[2.2.2]辛烷-2-羧酸叔丁酯的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432957B1 (en) 2001-06-29 2002-08-13 Kowa Co., Ltd. Piperazine derivative
AU2003280558A1 (en) * 2002-10-11 2004-05-04 Kowa Co., Ltd. Method for treatment of cancer
TW201006816A (en) 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
HUP1100166A2 (en) * 2011-03-29 2012-12-28 Sanofi Sa Reductive amination process for preparation of dronedarone using amine intermediary compound
WO2012158784A2 (en) * 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
PT2758060T (pt) * 2011-09-19 2018-01-24 ETH Zürich Moduladores de ror gama para o tratamento de complicações de diabetes ii
AR092348A1 (es) * 2012-07-11 2015-04-15 Hoffmann La Roche DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc
CN107614062A (zh) * 2015-03-12 2018-01-19 加利福尼亚大学董事会 用RORγ抑制剂治疗癌症的方法
ES2928904T3 (es) 2016-10-27 2022-11-23 Escalier Biosciences Bv Moduladores de ROR-gamma

Also Published As

Publication number Publication date
EP3532062A1 (en) 2019-09-04
MX2019004973A (es) 2019-09-19
IL266261A (en) 2019-06-30
RU2019115059A3 (enExample) 2020-12-18
IL266261B (en) 2022-07-01
AU2017348345A1 (en) 2019-05-30
MX392163B (es) 2025-03-21
US10905687B2 (en) 2021-02-02
KR20190096979A (ko) 2019-08-20
US20220175765A1 (en) 2022-06-09
CN110139652A (zh) 2019-08-16
AU2017348345B2 (en) 2022-01-27
US20230277527A1 (en) 2023-09-07
ES2928904T3 (es) 2022-11-23
RU2019115059A (ru) 2020-11-27
EP3532062B1 (en) 2022-07-20
BR112019008548A2 (pt) 2019-09-17
WO2018081558A1 (en) 2018-05-03
EP3532062A4 (en) 2020-04-15
JP7027437B2 (ja) 2022-03-01
US20240216361A1 (en) 2024-07-04
US20190269674A1 (en) 2019-09-05
RU2753490C2 (ru) 2021-08-17
JP2019535813A (ja) 2019-12-12
PH12019500949A1 (en) 2019-08-05
CN110139652B (zh) 2022-10-11
KR102598775B1 (ko) 2023-11-03
US20210069182A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
US20220175765A1 (en) Ror-gamma modulators
CA3150400A1 (en) Pyridine oxynitride, preparation method therefor and use thereof
US11827605B2 (en) Isoquinoline compounds and their use in treating AhR imbalance
CN113874021B (zh) Tyk2假激酶配体
JP2022553841A (ja) Ｔｙｋ２偽キナーゼリガンド
KR20220141331A (ko) P2x3 조정제
KR20190008411A (ko) 플로오르화 2-아미노-4-(치환된 아미노)페닐 카르밤산염 유도체
WO2017147161A1 (en) Treatment of dermatological disorders or conditions
CN112888479A (zh) 用于治疗病态状况的芳香型分子
EP3724163A1 (en) Fluorinated 4-(substituted amino)phenyl carbamate derivatives
JPH07503006A (ja) 認識力強化剤としてのジ置換多環式化合物
HK40012522B (en) Ror-gamma modulators
HK40012522A (en) Ror-gamma modulators
KR20220051351A (ko) Jak 억제제
CN115381824B (zh) 周期蛋白依赖性激酶9抑制剂的用途
HK40066192A (zh) Tyk2假激酶配体
HK40066192B (en) Tyk2 pseudokinase ligands
HK40080028B (en) Tyk2 pseudokinase ligands
CN120202198A (zh) 一种具有软药性质的硫醚类化合物、药物组合物及其用途
CN107759522A (zh) 羧酸类衍生物、其制备方法及其在医药上的用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240903